{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019849","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.444963+00:00","generated_at":"2026-06-25T19:06:41.489095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Graphite Bio Q1 net loss $25.8M; on track to dose first SCD patient in H2 2022","bullets":["Net loss $25.8M ($0.48 per share); R&D spend $18.2M, G&A $7.7M.","Cash, equivalents and investments $352.1M as of March 31, 2022; runway into Q4 2024.","GPH101 for sickle cell disease received FDA Fast Track Designation; first patient dosing target H2 2022, proof-of-concept data in 2023.","GPH102 for beta-thalassemia preclinical data presented at ASGCT; IND submission expected by mid-2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019849","json":"https://secwatch.observer/filing/0001564590-22-019849.json","markdown":"https://secwatch.observer/filing/0001564590-22-019849.md","text":"https://secwatch.observer/filing/0001564590-22-019849.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/0001564590-22-019849-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000156459022019849/grph-8k_20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:06:41.489095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}